Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.25 4.00 4.50 4.50 4.25 4.25 389,627 14:37:54
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.1 -2.7 - 6

Evgen Pharma Share Discussion Threads

Showing 1651 to 1675 of 1900 messages
Chat Pages: 76  75  74  73  72  71  70  69  68  67  66  65  Older
DateSubjectAuthorDiscuss
11/10/2019
15:06
Ps LWHL - just wondering, if you don�t mind sharing, which was your trade? Is it the 15.38 one or 15.46? Only asking as I think there�s been quite a bit of the usual inaccuracy regarding how they�ve been listed (buys or sells) . Still have no idea why, in this day and age, accurate trades can�t be listed. (Ps apologies, seems Apostrophes on my machine seem to send the font crazy for some reason)
pennyfalls
11/10/2019
14:58
LWHL...yes �sensible� always equates to successful ;o) Ps no idea what�s going on with these weird �font� glitches
pennyfalls
11/10/2019
14:50
I do not usually buy on a Friday afternoon, but I have made a small, and probably final, top up just now from some trading profit elsewhere. Have a good weekend all.
lovewinshatelosses
11/10/2019
09:38
One of the primary endpoints for the SAH trial is improved blood flow. Interesting new research has just been published; Vasodilator effects of sulforaphane in cerebral circulation: A critical role of endogenously produced hydrogen sulfide and arteriolar smooth muscle KATP and BK channels in the brain. hTTps://journals.sagepub.com/doi/abs/10.1177/0271678X19878284?journalCode=jcba A quote from the abstract; "Overall, we provide first evidence that SFN is a brain permeable compound that increases cerebral blood flow via a non-genomic mechanism" I assume this is a different mechanism of action to Nimodipine which is a calcium channel blocker.
pdt
10/10/2019
20:12
Which this one will hopefully prove be to also be of course (he puts down the glass of Shiraz and decides not to type anymore gibberish tonight).
lovewinshatelosses
10/10/2019
20:08
Sensible being those that are successful, of course.
lovewinshatelosses
10/10/2019
20:06
Yeah, I too am a fan of a gamble, even though I try to make sure most of my holdings follow more 'sensible' principles...
lovewinshatelosses
10/10/2019
19:20
Dear Artist Formerly Known as LWHL, Yes, missing out is sometimes a greater psychological pain than losing materially.. Although, it’s also the well-trodden road to the casino.. And I’m on it ;o)
pennyfalls
10/10/2019
19:12
Hi Pennyfalls. I did contact advfn and my attempts to change my name to LWHL was rebuffed, so perhaps I should now go by the name of the artist formally known as (or would that be a trade mark breach perhaps?!!) Anyway, I share your impetuosity but with a small cap stock like this one, I personally would feel much worse missing out on a multibagger than a total wipeout (please, please let it be the former though :)
lovewinshatelosses
10/10/2019
15:48
Hi Nelson and Lovesomuchtowinandhateslossesbadly (LWHL) ;o) Well LWHL..I think that applies to all of us with most companies if gut instinct isn’t followed. Although, in recent times, the only thing I really kick myself for is not following quite obvious technical markers for buying or selling stock. Obviously Evgen doesn’t fit this, as the catalyst is news - and I’m sure my reaction (either way) will be much the same as yours. I’ve almost certainly over-invested here, but I can be a tad impetuous !
pennyfalls
10/10/2019
15:40
I have long since given up trying to guess the direction of the share price here; I tend to veer towards pessimism when it comes to whether such drops are due to leaks, large holders de-risking or any number of other things. In this case, I am going to give them the benefit of the doubt, as I do not remember seeing anything dubious on this front since I have been invested here - so if things go well, I will pat myself on the back for holding my nerve, but if its a disaster, I will kick myself for not seeing the 'obvious' signs! GLA.
lovewinshatelosses
10/10/2019
14:05
I agree with your timeline for the news. LTH are also derisking as they watch previous profits evaporate.The share price is now below my average and represents 13.3% of my portfolio. I'm happy to divert other profits, as & when, into the lower price.
90005nelson
10/10/2019
13:41
Hi Nobby/Nelson.. Ive got to say Im not particularly �baffled� by the price movement, which seems to be following a well-trodden path between news to support of either 13.5p or 15p (broken), however, I am a little concerned that someone in some lab somewhere may have a shifter of something, although by no means saying this is the case; just a worry. I believe news is probably later in October to mid-November, so maybe it�s simply being walked down - although to do that, they need sellers (unless they�re trading between MMs to create an illusion) If these trades are valid, then someone, or some people , are certainly selling batches of rather large chunks. I see that there has been no Holdings RNS about the main holders, so at the moment it is pure guesswork - that people are de-risking/over-exposed/ want money for other things etc and feel that news isn�t coming until November. The other option is a leak, although maybe the Volume traded doesn�t equate to that.
pennyfalls
10/10/2019
11:02
I have to say I am a bit baffled by the recent price movement. Somebody clearly wants out for a reason which is beyond me as I don't think it is possible that anybody knows the result of the blinded trial yet. I agree that we probably won't get the results until November; cleaning up of data bases and data analysis always takes longer than expected in my experience. However, I can't really see why a short delay should cause such a pronounced fall.
nobbygnome
09/10/2019
22:15
Looks to me like the market isn't expecting results in October. So people worrying feeling over-exposed are reducing to a level they're comfortable holding at and also using the newly available funds for other shares.
90005nelson
09/10/2019
15:56
I’m a little concerned by some of the largish sells in recent days/weeks. I do wonder if someone has a sniff about the results direction? Today’s £23K was a sell, but posted as a buy as it was a delayed trade posting - and a couple of other £7Ks at a similar time. Could be people de-risking, MMs swapping shares between each other, or the possibility of a direction of travel leaking slowly? (Although to be fair, the same direction of travel chart-wise has preceded every other major rise)
pennyfalls
09/10/2019
10:39
Had a little top-up this morning
90005nelson
07/10/2019
17:02
Hi Pennyfalls, Thanks for your PM. I have sent a reply; apologies for the delay in getting back to you.
diamondstar1
04/10/2019
20:31
Must say there’s been some terrific knowledge on this board, and very lucky to have some dedicated Biotech people giving insight like Nobby, Timbo and Diamondstar. Been looking through some of their past posts regarding other shares, and makes for very interesting and insightful reading. Thanks to everyone else, Nelson et al, who’ve brought good discussion here too and Blakeysangel for such openness x
pennyfalls
03/10/2019
20:17
FAO Diamondstar.. sent you a Private Message, Cheers
pennyfalls
29/9/2019
17:27
Diamond star, There is no placebo as trial works like this, I was taking tamoxifen for 3 years, it stopped working, so added SFX01 with Tamoxifen and now it has kicked Tamoxifen back into action. So all the trial participants were on a drug that failed and STEM was tried to see if it would kick start the drug again. Hence no placebo because the drugs weren’t working so we couldn’t of stayed on the drug without STEM.. am I rambling lol.
blakeysangel
29/9/2019
17:15
I believe number 1) is false and number 2) is true. All the indications, shows delay mainly due to extra workload dataset. Which in turn means the mortality percentage (40%) has decreased to closer to 20% which in turn means that SFX-01 is a life saver in SAH trial, which in turn means that the secondary endpoint data is vital for it to keep its integrity.
90005nelson
29/9/2019
15:51
1) 40% of patients die within 30 days.2). we will fully maintain the blinded integrity of the secondary endpoint data, which in this trial are particularly important as they will form the basis of the primary endpoints in subsequent studies.3). Only one of the above statements can be true not both.
90005nelson
29/9/2019
12:44
The trial recruited a total of 104 patients, split into two arms in a randomised, double-blind, placebo-controlled trial.Wonder what the mathematical conundrum needed to be solved?
90005nelson
29/9/2019
12:12
Anyone worked out, Evgen has 20%+ more data than anticipated.?The clinical team is now focussed on the cleaning, validation and analysis of the large volume of data collected in this trial.
90005nelson
Chat Pages: 76  75  74  73  72  71  70  69  68  67  66  65  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200229 07:27:55